Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$127 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.7
Industry P/E
--
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
31,624,400
CFO
CN¥-1,813.13 Mln
EBITDA
CN¥-5,525.79 Mln
Net Profit
CN¥-2,727.52 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genetron Holdings (GTH)
| 9.2 | 2.6 | 9.2 | 34.0 | -58.1 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Genetron Holdings (GTH)
| 9.5 | -81.6 | -56.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early... screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China. Read more
Co-Founder, CEO & Chairman
Mr. Sizhen Wang
Co-Founder, CEO & Chairman
Mr. Sizhen Wang
Headquarters
Beijing
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Genetron Holdings Ltd (GTH) is $4.02 (NASDAQ) as of 28-Mar-2024 18:19 EDT. Genetron Holdings Ltd (GTH) has given a return of -58.13% in the last 3 years.
Since, TTM earnings of Genetron Holdings Ltd (GTH) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
-0.43
|
0.16
|
|
2020
|
-1.41
|
0.17
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Genetron Holdings Ltd (GTH) are Rs -- and Rs -- as of 03-Apr-2026.
Genetron Holdings Ltd (GTH) has a market capitalisation of $ 127 Mln as on 10-Apr-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Genetron Holdings Ltd (GTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.